OLF1R Olaines Kimiski - Farmaceitiska Rupnica

Olainfarm expands presence in Ukraine to be closer to the clients

Olainfarm expands presence in Ukraine to be closer to the clients

Olainfarm expanded its marketing team and updated its business model, setting up a fully operating representative office in Ukraine. Up to 25 professional Olainfarm employees provide a full-fledged presence in 14 cities, including strategically important cities as Kyiv, Dnepr, Kharkiv, Odessa, Lviv. The capacity expansion helped to raise the company's local impact by reaching 63,000 healthcare professionals and about 100,000 digital contacts in a 2020 campaign, executed in the second part of the year. As the base for the transformation process of the marketing model, an already established Olainfarm legal entity in Ukraine was used.

“The direct approach to the market allows us to have a powerful presence in Ukraine over a long period of time and opens new growth opportunities. Collecting customer insights and responding to healthcare needs is critical for success especially now when the communication happens almost exclusively in a digital form. This way we are closer to our customers and clients. Only by listening to them, we can fit their needs and demands. Presence in the largest 14 cities is a powerful enabler to our strategy that supports our mission to deliver high quality products that improve people's quality of life,” said Elena Bushberg, Member of the Management Board, CEO of Olainfarm, a part of Olainfarm Group companies.

The first approach to measure customers interest in Olainfarm key products was made in the second half of 2020 with a multichannel marketing project that ensured strong coverage for five key products of Olainfarm (Etacizin, Noophen, Adaptol, Furamag, Neiromedin) promotion for the medical community. Altogether the project covered 63,000 healthcare professionals (Gynaecologists, Urologists, Cardiologists, Neurologists, Family doctors) with calls and mailings and educational events on an online platform. The project revealed high interest and engagement in communication and contributed to the positive decision to expand company's presence in Ukraine.

Olainfarm, a part of Olainfarm Group, is one of the leading pharmaceutical companies in the Baltic States offering high quality medicine and chemical pharmaceutical products. The Group’s business strategy “FORWARD” highlights the main company’s vision – to become one of the TOP10 Central and Eastern European manufacturing companies by 2025.

With nearly 50 years of expertise, Olainfarm Group delivers sustainable healthcare products and services with added value to patients in more than 50 countries all over the world via its key subsidiaries – pharmaceutical company Olainfarm, food supplements & medical devices provider Silvanols, elastic & compression material producer Tonus Elast, pharmacy chain Latvijas aptieka and healthcare & diagnostics centres Diamed & Olainmed.

Additional information:  

Jānis Dubrovskis

Investor Relations Advisor of JSC Olainfarm

Phone:

Email:



EN
19/02/2021

Underlying

Reports on Olaines Kimiski - Farmaceitiska Rupnica

 PRESS RELEASE

Delisting of AS "Olainfarm” shares from the Baltic Main list

Delisting of AS "Olainfarm” shares from the Baltic Main list Delisting of AS "Olainfarm” shares from the Baltic Main list With this AS "Olainfarm” informs, that Nasdaq Riga decided on January 7, 2022 to approve the application of AS "Olainfarm” and to delist its shares (ISIN LV0000100501, Ticker OLF1R) from the Baltic Main List. The last listing day of AS "Olainfarm” is set to January 10, 2022. Additional information:  Jānis LeimanisJSC Olainfarm Member of the Management BoardTel. E-pasts:

 PRESS RELEASE

AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta

AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta AS "Olainfarm” akcijas izslēdz no Baltijas Oficiālā saraksta Ar šo AS "Olainfarm” informē, ka Nasdaq Riga š.g. 7. janvārī pieņēma lēmumu apstiprināt AS "Olainfarm” akciju (ISIN LV0000100501, Biržas kods OLF1R) izslēgšanu no Baltijas Oficiālā saraksta, par pēdējo akciju kotācijas dienu nosakot 2022. gada 10. janvāri. Papildu informācija:Jānis LeimanisAS “Olainfarm” valdes loceklisTel. E-pasts:

 PRESS RELEASE

Notification about results of final buy-back of shares

Notification about results of final buy-back of shares Notification about results of final buy-back of shares Target company Joint Stock Company " Olainfarm ", registration number  40003007246, legal address: Rupnicu str. 5, Olaine, LV-2114, Latvia, phone: (+371) 67013705, e-mail:  , website: , hereinafter - Target Company.  Offeror AS “AB CITY”, registration number 40203174414, date and place of registration 11.10.2018., Rīga, legal address: Ganību dambis 24D, Riga, LV-1005, e-mail:  , website: , hereinafter - Offeror. Number of shares offered for sale A total of 549 8...

 PRESS RELEASE

Paziņojums par galīgās akciju atpirkšanas rezultātiem

Paziņojums par galīgās akciju atpirkšanas rezultātiem Paziņojums par galīgās akciju atpirkšanas rezultātiem Mērķa sabiedrība Akciju sabiedrība „Olainfarm”, reģistrācijas numurs 40003007246, juridiskā adrese: Rūpnīcu iela 5, Olaine, Olaines novads, LV-2114, tālr. (+371) 67013705; e-pasts: , mājaslapas adrese: , turpmāk – Mērķa sabiedrība. Piedāvātājs AS “AB CITY”, reģistrācijas numurs 40203174414, reģistrācijas datums un vieta 11.10.2018., Rīga, juridiskā adrese: Ganību dambis 24D, Rīga, LV-1005, e-pasts: , mājaslapas adrese: , turpmāk - Piedāvātājs. Pārdošanai p...

 PRESS RELEASE

Paziņojums par galīgo akciju atpirkšanu

Paziņojums par galīgo akciju atpirkšanu Akciju sabiedrība “Olainfarm”, turpmāk – Sabiedrība, informē, ka ar Finanšu un kapitāla tirgus komisijas 2021. gada 28. decembra lēmumu Nr. 185 AS “AB CITY”, reģistrācijas numurs 40203174414, ir atļauts veikt Sabiedrības galīgo akciju atpirkšanu. Vienas akcijas cena galīgajā akciju atpirkšanā ir 9,26 EUR. Atpirkšanas cena ir noteikta saskaņā ar Finanšu instrumentu tirgus likuma 74. panta pirmās daļas 3. punktā noteikto metodi. Ieraksta datums tiek noteikts nākamā darba diena pēc informācijas par galīgo atpirkumu publikācijas oficiālajā izdevumā “...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch